$SESN "Vicineum in combination with AstraZeneca’s anti-PD-L1, Imfinzi (durvalumab)....We expect data from this study to guide additional combination potential and future trials." Plus the recent update on the outcome measures for CR and disease-free survival. Looks like there is something going on in this trial.
  • 6
6 Likes